xia access · Market access and HTA

Market access, from value proposition to reimbursement.

HTA submissions, EU joint clinical assessment, pricing and reimbursement, market access strategy and value communication.

Discuss your project Our services

Doctor talking with a patient and family member

The problem

Reimbursement is harder to secure and slower to achieve.

Evidence standards keep rising, the EU JCA adds a layer to every European launch, and international reference pricing and US MFN policy link prices across markets.

Our view

HTA assessor insight, manufacturer-side delivery.

We have worked inside NICE and on company submissions to NICE, SMC, AWMSG, NCPE, CDA-AMC and the EU JCA, including resubmissions and commercial offer preparation.

Questions we answer

What will NICE, SMC, AWMSG or NCPE challenge in our submission?
How do we prepare for PICO scoping under the JCA?
What price can our evidence defend?
How do we plan a successful resubmission?

xia access

Health technology assessment

Submissions written by people who have assessed them, with support before, during and after the submission.

NICE technology appraisals and HealthTech submissions
SMC, AWMSG and NCPE submissions and rapid reviews
CDA-AMC (Canada) reimbursement submissions
Early value assessment so trials capture the outcomes payers need
A clear, consistent value story across the clinical and economic sections
Submission project management, timelines and review cycles
Model adaptation and training for local affiliates
Advisory boards, expert elicitation and mock appraisal committees
Clarification responses, technical engagement and post-submission support
Resubmission strategy after negative recommendations and NICE appeal support
Briefing books for NICE Advice, EMA–HTA parallel consultation and joint scientific consultation
HTA benchmarking: what drove past decisions in your therapy area
Likelihood-of-success assessments and plans for missing comparator or immature data
Patient voice reviews and support for patient organisation input
AMCP-format dossiers for US payers

xia access

Value communication

A compelling, evidence-based value proposition, built early and told consistently.

Early aspirational payer value stories and evidence gap analysis
Evidence generation planning, prioritised with early economic modelling
Global value dossiers (GVDs)
Payer value stories, value propositions and payer question-and-answer guides
Payer-facing materials for clinicians and decision makers
Manuscripts on economic, statistical and burden-of-illness analyses and systematic reviews
Interactive global value dossiers
Value message testing and validation with payers
Publication strategy and planning
Advisory board materials and interview guides

xia access

EU JCA and regulatory

Ready for the EU HTA Regulation, from PICO to national follow-on.

JCA dossier development for medicines and devices
PICO scoping and evidence gap analysis
Joint scientific consultation preparation
JCA readiness assessment across EU member states (see our index)
National HTA adaptation after the JCA report
Aligning regulatory and HTA evidence strategies

xia access

Pricing, reimbursement and negotiations

Turning evidence into an agreed price.

Pricing and reimbursement strategy and launch sequencing
US most-favoured-nation (MFN) and international reference pricing analysis
Payer engagement support, including preparation for pricing meetings
Managed access and commercial arrangement design
Time-to-reimbursement and pricing landscape analysis
Payer negotiation materials and pricing scenarios
Innovative commercial models and deal structures
Tender and procurement support for medical technologies

xia access

Market access strategy

Access thinking from early development onwards.

Market access strategy and integrated evidence plans
Opportunity assessment and indication sequencing
Launch feasibility assessments for go/no-go decisions
Access to an expert panel of clinicians, payers and former assessors
Launch readiness and market support
Payer landscaping and stakeholder mapping
Adoption and uptake: local health system engagement, business cases and field team tools
Multi-market launch and uptake planning

Interactive

From early advice to patient access.

Every stage of the access pathway shapes the next. Select a stage to see where we come in.

Illustrative data and models, for demonstration only.

How an engagement runs

From access strategy to reimbursement and uptake.

01
Access strategy
Value story, evidence plan and launch sequencing, set before key decisions are locked.
02
Dossier and model
Submissions, GVDs and value materials that tell one consistent story.
03
Submission and review
Clarification questions, mock committees and technical engagement.
04
Price and uptake
Pricing scenarios, commercial offers and negotiation support.

Inside the HTA process

Led by a former NICE HTA Technical Lead and Analyst, who knows how committees read a submission.

Across HTA systems

NICE, SMC, AWMSG, NCPE, CDA‑AMC and the EU JCA, plus US pricing work.

Senior-led

The person who scopes your project builds the model and joins the meeting.

In health since 2015

More than a decade across clinical practice, public health, agencies and HTA.

Related insights

Our analysis on this.

All insights

19reference countries in the GLOBE basket

Pricing and access · October 2026

US MFN drug pricing: what it means for UK and European launches

US MFN drug pricing explained: GLOBE, GUARD and GENEROUS, reference baskets, the GDP (PPP) adjuster and what it means for UK, Irish and EU launch prices.

Read the analysis

8PICOs in the scope of the first published JCA

EU HTA · October 2026

JCA PICO scoping: how it works and what the first reports show

How PICO scoping works in the EU joint clinical assessment, what the first published JCA reports show, and how to plan SLRs and indirect comparisons for it.

Read the analysis

100 daysJCA dossier deadline from the first request

EU HTA · October 2026